Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.48 |
| ▸ | CA2 | P00918 | 13/20 | 0.48 |
| ▸ | CA12 | O43570 | 9/20 | 0.48 |
| ▸ | CA4 | P22748 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.40 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392422 | 0.92 | CA1 (0.49) | CA1CA2CA12CA4POLB | |
| SCHEMBL5402080 | 0.91 | KCNA5 (0.48) | KMT2ALMNAKCNA5MAPTKCNK3 | |
| SCHEMBL5398456 | 0.90 | CA2 (0.54) | CA1CA2CA12CA4POLB | |
| SCHEMBL5403070 | 0.88 | CA2 (0.49) | CA1CA2CA12CA4POLB | |
| SCHEMBL5394244 | 0.88 | KCNA5 (0.43) | KMT2ALMNAKCNA5MAPTKCNK3 | |
| SCHEMBL5414032 | 0.88 | CA2 (0.49) | CA1CA2CA12CA4POLB | |
| SCHEMBL5401634 | 0.86 | MAPT (0.44) | POLBKMT2ALMNAKCNA5MAPT | |
| SCHEMBL5392428 | 0.86 | CA1 (0.48) | CA1CA2CA12CA4POLB | |
| SCHEMBL5397644 | 0.86 | MAPT (0.48) | KMT2ALMNAKCNA5MAPTKCNK3 | |
| SCHEMBL5401053 | 0.86 | CA2 (0.55) | CA1CA2CA12CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | CA1 722/4885CA2 1987/4885CA12 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.